Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$24.27M+224.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ross Muken
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 415
- Beta
- 0.95
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.04
Financials
Revenue
$24.27M+224.4%Net Income
$-20.27MEBITDA
$-18.34MFree Cash Flow
$-11.79MEPS (diluted)
$-0.24Shares Outstanding (diluted)
85.51M+122.8%Operating Expenses
$33.76MCash & Debt
$93.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $77.27M | $-79.00M | $-1.17 |
| 2024 | $65.17M | $-62.49M | $-0.95 |
| 2023 | $62.37M | $-78.98M | $-1.22 |
| 2022 | $47.56M | $-87.45M | $-1.36 |
| 2021 | $40.45M | $-73.67M | $-1.33 |
| 2020 | $28.40M | $-39.34M | $-0.82 |
| 2019 | $25.36M | $-33.79M | $-0.53 |
Valuation
SOPHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (6)
- Newsfool.com·6d ago·Positive
SOPHiA: 3 Key Takeaways for Long-Term Investors SOPHiA expects 2026 revenue near $96 million. U.S. revenue grew 41% in the third quarter.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
SOPHiA GENETICS SA (SOPH) Presents at 2026 UBS Global Healthcare Conference Transcript SOPHiA GENETICS SA ( SOPH ) 2026 UBS Global Healthcare Conference November 9, 2026 10:15 AM EST Company Participants Jurgi Camblong - Co-Founder & Executive Chairman Kellen Sanger - Head of Strategy and Investor Relations Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·19d ago·Neutral
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.3 per share a year ago.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue was $24.3 million, up 25% year-over-year on a reported basis Gross margin was 65.7% on a reported basis and 72.8% on an adjusted basis, compared to 66.3% reported and 73.1% adjust…
View source ↗ - Newszacks.com·65d ago·Neutral
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last? SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗
Earnings
Tue, Mar 2(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise -21.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.24 vs $-0.20miss
- Tue, Aug 4$-0.26 vs $-0.21miss
- Tue, May 5$-0.27 vs $-0.23miss
- Tue, Mar 3$-0.28 vs $-0.24miss
- Tue, Nov 4$-0.30 vs $-0.20miss
- Tue, Aug 5$0.33 vs $-0.21beat
Estimates and results for SOPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SOPH officers and directors.
- Bought
- $278k
- Sold
- $4.1m
2 trades
76 trades
- Van Well Daansold
- Xu Zhenyusold
- Menu Philippesold
- Hibbs Kathy Lsold
- Camblong Jurgisold
- Van Well Daansold
- Cardoza Georgebought
- Muken Rossbought
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SOPH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
